Correction to: Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAcute Myeloid Leukemia Research · Chronic Myeloid Leukemia Treatments · Acute Lymphoblastic Leukemia research
Ashouri K, Chennapan K, Martynova A, Nazaretyan S, Ali A, Ginosyan AA, et al. “Post‐stem cell transplant maintenance in FLT3^mut^ acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib.” Eur J Haematol. 2024;5(2):423–27. https://doi.org/10.1002/jha2.885
The title of the letter should read “Post‐hematopoietic stem cell transplant FLT3 inhibitor maintenance therapy improves outcomes in acute myeloid leukemia: Real‐world insights and clinical implications.”
We apologize for this error.